# Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases

> **NCT03430947** · PHASE2 · TERMINATED · sponsor: **Technische Universität Dresden** · enrollment: 20 (actual)

## Conditions studied

- Malignant Melanoma Stage IV
- BRAF V600 Mutation
- Brain Metastases

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT03430947
- **Lead sponsor:** Technische Universität Dresden
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-01
- **Primary completion:** 2023-02-10
- **Final completion:** 2023-02-10
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Due to insufficient recruitment, the clinical trial was terminated prematurely
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03430947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03430947, "Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03430947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*